David W Ellison

List of Publications by Year
in descending order

139 papers	35,659 citations	23544 58 h-index	13758 129 g-index
143 all docs	143 docs citations	143 times ranked	31339 citing authors

#	Article	IF	Citations
1	Clinically Tractable Outcome Prediction of Non-WNT/Non-SHH Medulloblastoma Based on TPD52 IHC in a Multicohort Study. Clinical Cancer Research, 2022, 28, 116-128.	3.2	8
2	Intracranial mesenchymal tumors with FETâ€CREB fusion are composed of at least two epigenetic subgroups distinct from meningioma and extracranial sarcomas. Brain Pathology, 2022, 32, e13037.	2.1	11
3	SIOP Ependymoma I: Final results, long-term follow-up, and molecular analysis of the trial cohortâ€"A BIOMECA Consortium Study. Neuro-Oncology, 2022, 24, 936-948.	0.6	16
4	The molecular characteristics of lowâ€grade and highâ€grade areas in desmoplastic infantile astrocytoma/ganglioglioma. Neuropathology and Applied Neurobiology, 2022, 48, .	1.8	5
5	Vorinostat and isotretinoin with chemotherapy in young children with embryonal brain tumors: A report from the Pediatric Brain Tumor Consortium (PBTC-026). Neuro-Oncology, 2022, 24, 1178-1190.	0.6	13
6	Revised clinical and molecular risk strata define the incidence and pattern of failure in medulloblastoma following risk-adapted radiotherapy and dose-intensive chemotherapy: results from a phase III multi-institutional study. Neuro-Oncology, 2022, 24, 1166-1175.	0.6	2
7	Phase II Study of Intravenous Etoposide in Patients with Relapsed Ependymoma (CNS 2001 04). Neuro-Oncology Advances, 2022, 4, vdac053.	0.4	0
8	A rare variant analysis framework using public genotype summary counts to prioritize disease-predisposition genes. Nature Communications, 2022, 13, 2592.	5.8	6
9	PATH-03. Clinically Tractable Outcome Prediction of Group 3/4 Medulloblastoma Based on TPD52 Immunohistochemistry: a Multicohort Study. Neuro-Oncology, 2022, 24, i158-i158.	0.6	0
10	ATRT-22. Outcomes for children with recurrent atypical teratoid rhabdoid tumor: A single institution study with updated molecular and germline analysis. Neuro-Oncology, 2022, 24, i8-i8.	0.6	1
11	Intracranial mesenchymal tumor with FETâ€CREB fusionâ€"A unifying diagnosis for the spectrum of intracranial myxoid mesenchymal tumors and angiomatoid fibrous histiocytomaâ€like neoplasms. Brain Pathology, 2021, 31, e12918.	2.1	44
12	Subependymal giant cell astrocytomas are characterized by mTORC1 hyperactivation, a very low somatic mutation rate, and a unique gene expression profile. Modern Pathology, 2021, 34, 264-279.	2.9	16
13	Outcome and molecular analysis of young children with choroid plexus carcinoma treated with non-myeloablative therapy: results from the SJYC07 trial. Neuro-Oncology Advances, 2021, 3, vdaa168.	0.4	6
14	Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q. Neuro-Oncology, 2021, 23, 1360-1370.	0.6	46
15	Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. Journal of Clinical Oncology, 2021, 39, 807-821.	0.8	40
16	Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03). Journal of Clinical Oncology, 2021, 39, 822-835.	0.8	106
17	Relevance of Molecular Groups in Children with Newly Diagnosed Atypical Teratoid Rhabdoid Tumor: Results from Prospective St. Jude Multi-institutional Trials. Clinical Cancer Research, 2021, 27, 2879-2889.	3.2	35
18	Cross-Species Genomics Reveals Oncogenic Dependencies in ZFTA/C11orf95 Fusionâ€"Positive Supratentorial Ependymomas. Cancer Discovery, 2021, 11, 2230-2247.	7.7	39

#	Article	IF	Citations
19	The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro-Oncology, 2021, 23, 1231-1251.	0.6	4,534
20	Genomes for Kids: The Scope of Pathogenic Mutations in Pediatric Cancer Revealed by Comprehensive DNA and RNA Sequencing. Cancer Discovery, 2021, 11, 3008-3027.	7.7	88
21	Abstract 642: Genomes for Kids: Comprehensive DNA and RNA sequencing defining the scope of actionable mutations in pediatric cancer. , 2021, , .		0
22	Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial neuroepithelial tumors. Acta Neuropathologica, 2021, 142, 827-839.	3.9	33
23	St. Jude Cloud: A Pediatric Cancer Genomic Data-Sharing Ecosystem. Cancer Discovery, 2021, 11, 1082-1099.	7.7	109
24	Clear cell meningiomas are defined by a highly distinct DNA methylation profile and mutations in SMARCE1. Acta Neuropathologica, 2021, 141, 281-290.	3.9	31
25	Anatomic Neuroimaging Characteristics of Posterior Fossa Type A Ependymoma Subgroups. American Journal of Neuroradiology, 2021, 42, 2245-2250.	1.2	9
26	Serial assessment of measurable residual disease in medulloblastoma liquid biopsies. Cancer Cell, 2021, 39, 1519-1530.e4.	7.7	64
27	BIOM-36. SERIAL ASSESSMENT OF MEASURABLE RESIDUAL DISEASE IN MEDULLOBLASTOMA LIQUID BIOPSIES. Neuro-Oncology, 2021, 23, vi18-vi19.	0.6	0
28	The landscape of coding RNA editing events in pediatric cancer. BMC Cancer, 2021, 21, 1233.	1.1	7
29	Isomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYBL1 or MYB and a benign disease course. Acta Neuropathologica, 2020, 139, 193-209.	3.9	83
30	YAP1-fusions in pediatric NF2-wildtype meningioma. Acta Neuropathologica, 2020, 139, 215-218.	3.9	45
31	Risk-adapted therapy and biological heterogeneity in pineoblastoma: integrated clinico-pathological analysis from the prospective, multi-center SJMB03 and SJYC07 trials. Acta Neuropathologica, 2020, 139, 259-271.	3.9	36
32	Clinicopathologic and molecular features of intracranial desmoplastic small round cell tumors. Brain Pathology, 2020, 30, 213-225.	2.1	20
33	Tectal glioma harbors high rates of KRAS G12R and concomitant KRAS and BRAF alterations. Acta Neuropathologica, 2020, 139, 601-602.	3.9	13
34	Molecular subgrouping of primary pineal parenchymal tumors reveals distinct subtypes correlated with clinical parameters and genetic alterations. Acta Neuropathologica, 2020, 139, 243-257.	3.9	50
35	Diffuse Midline Glioma With Osseous Metastases at Diagnosis: A Case Report. Journal of Pediatric Hematology/Oncology, 2020, 42, e673-e676.	0.3	5
36	CICERO: a versatile method for detecting complex and diverse driver fusions using cancer RNA sequencing data. Genome Biology, 2020, 21, 126.	3.8	74

#	Article	IF	Citations
37	Pediatric Posterior Fossa Medulloblastoma: The Role of Diffusion Imaging in Identifying Molecular Groups. Journal of Neuroimaging, 2020, 30, 503-511.	1.0	9
38	cIMPACTâ€NOW update 7: advancing the molecular classification of ependymal tumors. Brain Pathology, 2020, 30, 863-866.	2.1	168
39	Patient-derived orthotopic xenografts of pediatric brain tumors: a St. Jude resource. Acta Neuropathologica, 2020, 140, 209-225.	3.9	45
40	Germline Elongator mutations in Sonic Hedgehog medulloblastoma. Nature, 2020, 580, 396-401.	13.7	94
41	A 4â€Yearâ€Old Girl With a Supratentorial Mass. Brain Pathology, 2020, 30, 421-422.	2.1	0
42	Risk stratification in pediatric low-grade glioma and glioneuronal tumor treated with radiation therapy: an integrated clinicopathologic and molecular analysis. Neuro-Oncology, 2020, 22, 1203-1213.	0.6	12
43	Integrated Molecular and Clinical Analysis of 1,000 Pediatric Low-Grade Gliomas. Cancer Cell, 2020, 37, 569-583.e5.	7.7	244
44	Clinical impact of combined epigenetic and molecular analysis of pediatric low-grade gliomas. Neuro-Oncology, 2020, 22, 1474-1483.	0.6	39
45	Miniâ€symposium in medulloblastoma genomics in the modern molecular era. Brain Pathology, 2020, 30, 661-663.	2.1	16
46	Clinical, imaging, and molecular analysis of pediatric pontine tumors lacking characteristic imaging features of DIPG. Acta Neuropathologica Communications, 2020, 8, 57.	2.4	32
47	Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. Cancer Discovery, 2020, 10, 942-963.	7.7	157
48	Phase II study of alisertib as a single agent in recurrent or progressive atypical teratoid rhabdoid tumors.. Journal of Clinical Oncology, 2020, 38, 10542-10542.	0.8	4
49	Enrichment of heterozygous germline RECQL4 loss-of-function variants in pediatric osteosarcoma. Journal of Physical Education and Sports Management, 2019, 5, a004218.	0.5	26
50	A single-center study of the clinicopathologic correlates of gliomas with a MYB or MYBL1 alteration. Acta Neuropathologica, 2019, 138, 1091-1092.	3.9	45
51	Dedifferentiation in SDH-Deficient Gastrointestinal Stromal Tumor: A Report With Histologic, Immunophenotypic, and Molecular Characterization. Pediatric and Developmental Pathology, 2019, 22, 492-498.	0.5	15
52	Myc and Loss of p53 Cooperate to Drive Formation of Choroid Plexus Carcinoma. Cancer Research, 2019, 79, 2208-2219.	0.4	15
53	From uncertainty to pathogenicity: clinical and functional interrogation of a rare TP53 in-frame deletion. Journal of Physical Education and Sports Management, 2019, 5, a003921.	0.5	4
54	cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAFV600E mutation. Acta Neuropathologica, 2019, 137, 683-687.	3.9	170

#	Article	IF	Citations
55	Clinical genome sequencing uncovers potentially targetable truncations and fusions of MAP3K8 in spitzoid and other melanomas. Nature Medicine, 2019, 25, 597-602.	15.2	61
56	Conformal Radiation Therapy for Pediatric Ependymoma, Chemotherapy for Incompletely Resected Ependymoma, and Observation for Completely Resected, Supratentorial Ependymoma. Journal of Clinical Oncology, 2019, 37, 974-983.	0.8	154
57	Molecular grouping and outcomes of young children with newly diagnosed ependymoma treated on the multi-institutional SJYC07 trial. Neuro-Oncology, 2019, 21, 1319-1330.	0.6	63
58	EZHIP/CXorf67 mimics K27M mutated oncohistones and functions as an intrinsic inhibitor of PRC2 function in aggressive posterior fossa ependymoma. Neuro-Oncology, 2019, 21, 878-889.	0.6	106
59	Septal dysembryoplastic neuroepithelial tumor: a comprehensive clinical, imaging, histopathologic, and molecular analysis. Neuro-Oncology, 2019, 21, 800-808.	0.6	38
60	H3.3 K27M depletion increases differentiation and extends latency of diffuse intrinsic pontine glioma growth in vivo. Acta Neuropathologica, 2019, 137, 637-655.	3.9	85
61	Medulloblastoma. Nature Reviews Disease Primers, 2019, 5, 11.	18.1	376
62	The molecular landscape of ETMR at diagnosis and relapse. Nature, 2019, 576, 274-280.	13.7	94
63	Histone H3.3 K27M Accelerates Spontaneous Brainstem Glioma and Drives Restricted Changes in Bivalent Gene Expression. Cancer Cell, 2019, 35, 140-155.e7.	7.7	194
64	Structure and evolution of double minutes in diagnosis and relapse brain tumors. Acta Neuropathologica, 2019, 137, 123-137.	3.9	63
65	OR02-1 DNA Methylation Profiling in Pediatric Adrenocortical Tumors Reveals Distinct Methylation Signatures with Prognostic Significance: A Report from the International Pediatric Adrenocortical Tumor Registry. Journal of the Endocrine Society, 2019, 3, .	0.1	0
66	Real-time sharing of comprehensive clinical genomics sequencing data in St. Jude Cloud.. Journal of Clinical Oncology, 2019, 37, 10019-10019.	0.8	0
67	Atypical teratoid/rhabdoid tumor with retained <scp>INI</scp>1 (<scp>SMARCB1</scp>) expression and loss of <scp>BRG</scp>1 (<scp>SMARCA4</scp>). Neuropathology, 2018, 38, 305-308.	0.7	26
68	DNA methylation-based classification of central nervous system tumours. Nature, 2018, 555, 469-474.	13.7	1,872
69	Outcomes After Reirradiation for Recurrent Pediatric Intracranial Ependymoma. International Journal of Radiation Oncology Biology Physics, 2018, 100, 507-515.	0.4	71
70	Pediatric low-grade gliomas: next biologically driven steps. Neuro-Oncology, 2018, 20, 160-173.	0.6	116
71	Clinical cancer genomic profiling by three-platform sequencing of whole genome, whole exome and transcriptome. Nature Communications, 2018, 9, 3962.	5.8	142
72	Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial. Lancet Oncology, The, 2018, 19, 768-784.	5.1	151

#	Article	IF	Citations
73	Molecularly defined diffuse leptomeningeal glioneuronal tumor (DLGNT) comprises two subgroups with distinct clinical and genetic features. Acta Neuropathologica, 2018, 136, 239-253.	3.9	118
74	A De Novo Mouse Model of C11orf95-RELA Fusion-Driven Ependymoma Identifies Driver Functions in Addition to NF-Î²B. Cell Reports, 2018, 23, 3787-3797.	2.9	53
75	Heterogeneity within the PF-EPN-B ependymoma subgroup. Acta Neuropathologica, 2018, 136, 227-237.	3.9	86
76	Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas. Acta Neuropathologica, 2018, 136, 211-226.	3.9	199
77	Outcomes for young children with molecularly defined ependymoma treated on the multi-institutional SJYC07 clinical trial.. Journal of Clinical Oncology, 2018, 36, 10548-10548.	0.8	1
78	Evaluation of age-dependent treatment strategies for children and young adults with pineoblastoma: analysis of pooled European Society for Paediatric Oncology (SIOP-E) and US Head Start data. Neuro-Oncology, 2017, 19, now234.	0.6	33
79	Pediatric low-grade gliomas: implications of the biologic era. Neuro-Oncology, 2017, 19, now209.	0.6	73
80	Clear cell sarcoma of kidney involving a horseshoe kidney and harboring EGFR internal tandem duplication. Pediatric Blood and Cancer, 2017, 64, e26602.	0.8	14
81	Low-grade spinal glioneuronal tumors with BRAF gene fusion and 1p deletion but without leptomeningeal dissemination. Acta Neuropathologica, 2017, 134, 159-162.	3.9	33
82	Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy. Acta Neuropathologica, 2017, 133, 1-3.	3.9	120
83	Surgical and molecular considerations in the treatment of pediatric thalamopeduncular tumors. Journal of Neurosurgery: Pediatrics, 2017, 20, 247-255.	0.8	16
84	cIMPACTâ€NOW (the consortium to inform molecular and practical approaches to CNS tumor) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 30 27, 851-852.	2.1	63
85	The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. Acta Neuropathologica, 2017, 133, 5-12.	3.9	271
86	PTEN Signaling in the Postnatal Perivascular Progenitor Niche Drives Medulloblastoma Formation. Cancer Research, 2017, 77, 123-133.	0.4	20
87	Molecular pathology of paediatric central nervous system tumours. Journal of Pathology, 2017, 241, 159-172.	2.1	51
88	DNA methylation analysis of paediatric low-grade astrocytomas identifies a tumour-specific hypomethylation signature in pilocytic astrocytomas. Acta Neuropathologica Communications, 2016, 4, 54.	2.4	17
89	PNR-08NEWLY DISCOVERED ONCOGENES DRIVING AND MAINTAINING CHOROID PLEXUS CARCINOMA PROVIDE POTENTIALLY DRUGGABLE TARGETS. Neuro-Oncology, 2016, 18, iii8.2-iii8.	0.6	0
90	Epithelioid Glioblastomas and Anaplastic Epithelioid Pleomorphic Xanthoastrocytomasâ€"Same Entity or First Cousins?. Brain Pathology, 2016, 26, 215-223.	2.1	95

#	Article	IF	Citations
91	Cancer-associated DDX3X mutations drive stress granule assembly and impair global translation. Scientific Reports, 2016, 6, 25996.	1.6	121
92	Case Report of Spontaneous Resolution of a Congenital Glioblastoma. Pediatrics, 2016, 137, .	1.0	20
93	Quantitative imaging analysis of posterior fossa ependymoma location in children. Child's Nervous System, 2016, 32, 1441-1447.	0.6	20
94	The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathologica, 2016, 131, 803-820.	3.9	12,144
95	Relative ADC and Location Differ between Posterior Fossa Pilocytic Astrocytomas with and without Gangliocytic Differentiation. American Journal of Neuroradiology, 2016, 37, 2370-2375.	1.2	4
96	Custom Gene Capture and Next-Generation Sequencing to Resolve Discordant ALK Status by FISHÂand IHC in Lung Adenocarcinoma. Journal of Thoracic Oncology, 2016, 11, 1891-1900.	0.5	37
97	Multi-organ Mapping of Cancer Risk. Cell, 2016, 166, 1132-1146.e7.	13.5	128
98	Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology. Acta Neuropathologica, 2016, 131, 833-845.	3.9	288
99	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. Cancer Discovery, 2016, 6, 154-165.	7.7	372
100	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Cell, 2016, 164, 1060-1072.	13.5	702
101	Prevalence of RNA Editing Events Affecting Coding Regions in Pediatric Leukemia. Blood, 2016, 128, 3928-3928.	0.6	0
102	Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia Caused by a Novel R782G Mutation in CSF1R. Scientific Reports, 2015, 5, 10042.	1.6	22
103	MPTH-26MOLECULAR REFINEMENT OF PEDIATRIC POSTERIOR FOSSA EPENDYMOMA. Neuro-Oncology, 2015, 17, v144.1-v144.	0.6	0
104	Gorlin syndrome and desmoplastic medulloblastoma: Report of 3 cases with unfavorable clinical course and novel mutations. Pediatric Blood and Cancer, 2015, 62, 1855-1858.	0.8	6
105	Molecular Heterogeneity in a Patient-Derived Glioblastoma Xenoline Is Regulated by Different Cancer Stem Cell Populations. PLoS ONE, 2015, 10, e0125838.	1.1	25
106	Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. Cancer Cell, 2015, 27, 728-743.	7.7	933
107	Germline Mutations in Predisposition Genes in Pediatric Cancer. New England Journal of Medicine, 2015, 373, 2336-2346.	13.9	949
108	Combined MYC and P53 Defects Emerge at Medulloblastoma Relapse and Define Rapidly Progressive, Therapeutically Targetable Disease. Cancer Cell, 2015, 27, 72-84.	7.7	165

#	Article	IF	Citations
109	The Genomic Landscape of Childhood and Adolescent Melanoma. Journal of Investigative Dermatology, 2015, 135, 816-823.	0.3	148
110	Molecular Characterization of Choroid Plexus Tumors Reveals Novel Clinically Relevant Subgroups. Clinical Cancer Research, 2015, 21, 184-192.	3.2	84
111	An in vivo screen identifies ependymoma oncogenes and tumor-suppressor genes. Nature Genetics, 2015, 47, 878-887.	9.4	62
112	Multiple Molecular Data Sets and the Classification of Adult Diffuse Gliomas. New England Journal of Medicine, 2015, 372, 2555-2557.	13.9	33
113	Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehogâ€“Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. Journal of Clinical Oncology, 2015, 33, 2646-2654.	0.8	368
114	CONSERTING: integrating copy-number analysis with structural-variation detection. Nature Methods, 2015, 12, 527-530.	9.0	68
115	Subsequent neoplasms in survivors of childhood central nervous system tumors: risk after modern multimodal therapy. Neuro-Oncology, 2015, 17, 448-456.	0.6	44
116	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. Blood, 2015, 126, 481-481.	0.6	0
117	Phase II Trial of Erlotinib during and after Radiotherapy in Children with Newly Diagnosed High-Grade Gliomas. Frontiers in Oncology, 2014, 4, 67.	1.3	31
118	C11ORF95-RELA FUSIONS DRIVE ONCOGENIC NF-KB SIGNALING IN EPENDYMOMA. Neuro-Oncology, 2014, 16, iii16-iii16.	0.6	1
119	The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes. Nature Communications, 2014, 5, 3630.	5.8	342
120	C11orf95â€“RELA fusions drive oncogenic NF-ÎºB signalling in ependymoma. Nature, 2014, 506, 451-455.	13.7	559
121	<scp>I</scp>nternational <scp>S</scp>ociety of <scp>N</scp>europathologyâ€<scp>H</scp>aarlem <scp>C</scp>onsensus <scp>G</scp>uidelines for <scp>N</scp>ervous <scp>S</scp>ystem <scp>T</scp>umor <scp>C</scp>lassification and <scp>G</scp>rading. Brain Pathology, 2014, 24, 429-435.	2.1	499
122	The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nature Genetics, 2014, 46, 444-450.	9.4	871
123	Recurrent Somatic Structural Variations Contribute to Tumorigenesis in Pediatric Osteosarcoma. Cell Reports, 2014, 7, 104-112.	2.9	583
124	Incidence of Germline Mutations in Cancer-Predisposition Genes in Children with Hematologic Malignancies: a Report from the Pediatric Cancer Genome Project. Blood, 2014, 124, 127-127.	0.6	9
125	A prospective phase II study to determine the efficacy of GDC 0449 (vismodegib) in adults with recurrent medulloblastoma (MB): A Pediatric Brain Tumor Consortium study (PBTC 25B).. Journal of Clinical Oncology, 2013, 31, 2035-2035.	0.8	8
126	Copy Number Gain of 1q25 Predicts Poor Progression-Free Survival for Pediatric Intracranial Ependymomas and Enables Patient Risk Stratification: A Prospective European Clinical Trial Cohort Analysis on Behalf of the Children's Cancer Leukaemia Group (CCLG), SociÃ©tÃ© FranÃ§aise d'Oncologie PÃ©diatrique (SFOP), and International Society for Pediatric Oncology (SIOP). Clinical Cancer Research, 2012, 18, 2001-2011.	3.2	111

#	Article	IF	Citations
127	Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathologica, 2012, 123, 465-472.	3.9	1,536
128	A prognostic gene expression signature in infratentorial ependymoma. Acta Neuropathologica, 2012, 123, 727-738.	3.9	148
129	Distinct disease-risk groups in pediatric supratentorial and posterior fossa ependymomas. Acta Neuropathologica, 2012, 124, 247-257.	3.9	101
130	Use of whole genome sequencing to identify novel mutations in distinct subgroups of medulloblastoma.. Journal of Clinical Oncology, 2012, 30, 9518-9518.	0.8	0
131	Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathologica, 2011, 121, 381-396.	3.9	474
132	Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts. Journal of Negative Results in BioMedicine, 2011, 10, 7.	1.4	239
133	Definition of Disease-Risk Stratification Groups in Childhood Medulloblastoma Using Combined Clinical, Pathologic, and Molecular Variables. Journal of Clinical Oncology, 2011, 29, 1400-1407.	0.8	263
134	Childhood medulloblastoma: novel approaches to the classification of a heterogeneous disease. Acta Neuropathologica, 2010, 120, 305-316.	3.9	107
135	Survival and Prognostic Factors of Early Childhood Medulloblastoma: An International Meta-Analysis. Journal of Clinical Oncology, 2010, 28, 4961-4968.	0.8	273
136	Integrated Genomics Identifies Five Medulloblastoma Subtypes with Distinct Genetic Profiles, Pathway Signatures and Clinicopathological Features. PLoS ONE, 2008, 3, e3088.	1.1	606
137	Î²-Catenin Status Predicts a Favorable Outcome in Childhood Medulloblastoma: The United Kingdom Children's Cancer Study Group Brain Tumour Committee. Journal of Clinical Oncology, 2005, 23, 7951-7957.	0.8	411
138	Morphophenotypic Variation Predicts Clinical Behavior in Childhood Non-Desmoplastic Medulloblastomas. Journal of Neuropathology and Experimental Neurology, 2003, 62, 627-632.	0.9	107
139	Phase II study of alisertib as a single agent for treating recurrent or progressive atypical teratoid/rhabdoid tumor. Neuro-Oncology, 0, , .	0.6	7